---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-008195"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T05:02:38.949538+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Telomir announces Telomir-1 reverses calcium dysregulation in human cell lines

## Summary
- Telomir-1 fully reversed calcium dysregulation in human keratinocyte (HaCaT) and retinal (ARPE-19) cell lines under oxidative stress.
- Treatment also reduced oxidative stress, preserved cellular integrity, and prevented cell death; untreated cells showed degeneration.
- Telomir is advancing preclinical studies toward human trials for neurodegenerative, retinal, and metabolic diseases.
- The study was conducted in multiple human cell lines, supporting Telomir-1 as a potential first-in-class therapy for aging-related conditions.

## SEC filing metadata
- accession: 0001493152-25-008195
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225008195/0001493152-25-008195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225008195/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-008195
- JSON: https://secwatch.observer/filing/0001493152-25-008195.json
- Plain text: https://secwatch.observer/filing/0001493152-25-008195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.